Table 3.
Effect of erythromycin coadministration on the pharmacokinetic parameters of monoethylglycinexylidide (MEGX) and glycinexylidide (GX).
| Patients with cirrhosis | ||||||
|---|---|---|---|---|---|---|
| Healthy subjects | Child's class A | Child's class C | ||||
| Parameters | Placebo | Erythromycin | Placebo | Erythromycin | Placebo | Erythromycin |
| MEGX | ||||||
| AUC0, 12 (ng ml, 1 h) | 665 ± 270 | 886 ± 498* | 312 ± 86††† | 405 ± 123*††† | 281 ± 119††† | 347 ± 115*††† |
| Ratio % (95% CI) | 129 (102, 156) | 129 (102, 156) | 127 (110, 144) | |||
| Cmax (ng ml, 1) | 108 ± 64 | 141 ± 114 | 95 ± 79 | 95 ± 73 | 80 ± 69 | 73 ± 67 |
| Ratio 5 (95%CI) | 130 (80, 180) | 110 (62, 158) | 107 (85, 130) | |||
| tmax (h)‡ | 1 (0.25, 2.5) | 1.5 (0.25, 8) | 1 (0.25, 6) | 1 (0.25, 4) | 7 (0.5, 10)† | 8 (2.5, 10)† |
| Ratio % (95% CI) | 139 (31, 247) | 121 (69, 173) | 132 (85, 180) | |||
| GX | ||||||
| AUC0, 12 (ng ml, 1 h) | 315 ± 170 | 233 ± 110 | 136 ± 90†† | 80 ± 65†† | 104 ± 70†† | 95 ± 60†† |
| Ratio % (95% CI) | 80 (45, 115) | 80 (49, 111) | 95 (49, 141) | |||
| Cmax (ng ml, 1) | 71 ± 61 | 62 ± 50 | 46 ± 35 | 36 ± 26 | 21 ± 18 | 28 ± 24 |
| Ratio % (95% CI) | 100 (50, 150) | 71 (34, 107) | 160 (95, 225) | |||
| tmax (h)‡ | 6 (1, 10) | 8 (6, 10) | 7 (1.5, 10) | 8 (6, 10) | 9 (1, 10) | 10 (8, 10) |
| Ratio % (95% CI) | 129 (100, 157) | 142 (30, 255) | 163 (74, 252) | |||
Data are presented as means (s.d.).
*
P < 0.05 vs. placebo.
†
P < 0.05
††
P < 0.01
†††
P < 0.001 vs. healthy volunteers.
‡
Median value (range).